Growth-hormone pathway
Explore source-listed topics such as Tesamorelin and Sermorelin before a provider conversation.
Open the pathwayPeptides / 003
This source-aligned overview contains educational peptide topics published by Vitrex. A licensed provider determines whether any option is appropriate after a confidential intake.
Discuss with a providerPeptide pathways
These source-listed pathways organize an educational conversation. A licensed provider decides what, if anything, is appropriate after review.
Explore source-listed topics such as Tesamorelin and Sermorelin before a provider conversation.
Open the pathwayReview source-listed recovery and performance discussion topics.
Open the pathwayReview source-listed skin and regenerative-biology topics.
Open the pathwayRead source-listed contexts for focus, sleep, and calm conversations.
Open the pathwayStart with the right questions for a confidential provider conversation.
Open the pathwayReview source-listed longevity and immune-support topics.
Open the pathwayApproved GLP-1 medicines separated from research peptides.
Open the pathwayApproved hormone therapy, non-hormonal options and the peptide claims.
Open the pathway
Vitrex-listed context
Each card offers source-aligned educational context. It is not an indication, dosage, or medical recommendation.
Products require evaluation and approval by a licensed provider. Individual results are not implied or guaranteed.
Core reference / 01
Metabolism & body-composition context
Vitrex lists Tesamorelin in its metabolism and body-composition research pathway. It is a topic to discuss with a licensed provider after a confidential intake, not a promised outcome.
Learn more → Discuss with a provider ↗Growth-hormone pathway context
Vitrex lists Sermorelin in its growth-hormone pathway context. A provider determines whether this topic is relevant after reviewing an individual medical intake.
Learn more → Discuss with a provider ↗Longevity & cellular-support context
Vitrex includes SS-31 among its longevity and cellular-support research topics. It requires clinician review; this catalog does not determine suitability or expected results.
Learn more → Discuss with a provider ↗Skin & regenerative-biology context
Vitrex lists GHK-Cu in its skin and regenerative-biology pathway. The listing is educational, and a licensed provider decides whether a clinical conversation is appropriate.
Learn more → Discuss with a provider ↗Recovery & gut-support context
Vitrex includes BPC-157 in recovery and gut-support research contexts. It is a provider-discussion topic only; medical review is required before any care decision.
Learn more → Discuss with a provider ↗Recovery & performance context
Vitrex lists TB-500 in its recovery and performance research context. A provider—not this page—determines whether the topic belongs in an individual care conversation.
Learn more → Discuss with a provider ↗Sleep & calm context
Vitrex includes DSIP in its sleep and calm research pathway. The listing does not replace a clinician evaluation of sleep concerns or other health needs.
Learn more → Discuss with a provider ↗Focus & calm context
Vitrex lists Selank among its focus and calm research topics. A provider can assess individual context and appropriateness only through a confidential review.
Learn more → Discuss with a provider ↗Extended reference / 02
Focus & calm context
Vitrex includes Semax in its focus and calm research pathway. It is shown as educational source context rather than medical advice or a recommendation.
Learn more → Discuss with a provider ↗Metabolism & longevity context
Vitrex lists MOTS-c across metabolism and longevity research contexts. The source listing is for education; a licensed provider determines relevance through confidential review.
Learn more → Discuss with a provider ↗Growth-hormone secretagogue context
Vitrex lists Ipamorelin within its growth-hormone secretagogue reference pathway. It is a topic for a licensed provider to evaluate during a confidential intake, not a promised result.
Learn more → Discuss with a provider ↗Growth-hormone releasing context
Vitrex lists CJC-1295 in its growth-hormone releasing research pathway. Any use is subject to provider evaluation and approval and is not an indication or dosage recommendation.
Learn more → Discuss with a provider ↗Appetite & secretagogue context
Vitrex references GHRP-6 as source-listed research context. It is a subject for provider discussion after intake, not a promised outcome.
Learn more → Discuss with a provider ↗Growth-hormone secretagogue context
Vitrex lists GHRP-2 within its secretagogue reference material. It requires evaluation and approval by a licensed provider before any consideration.
Learn more → Discuss with a provider ↗Metabolism & body-composition context
Vitrex references AOD-9604 in its metabolism and body-composition research pathway. It is educational context only, not a medical recommendation.
Learn more → Discuss with a provider ↗Immune-modulation context
Vitrex lists Thymosin Alpha-1 within its immune-modulation reference material. Any use is subject to provider evaluation and approval.
Learn more → Discuss with a provider ↗Antimicrobial-peptide context
Vitrex references LL-37 as source-listed research context. It is a topic to raise with a licensed provider, not an indication or dosage.
Learn more → Discuss with a provider ↗Inflammation-response context
Vitrex lists KPV within its inflammation-response reference pathway. It is educational source context and not a medical recommendation.
Learn more → Discuss with a provider ↗Cellular-longevity context
Vitrex references Epithalon in its cellular-longevity research material. Any consideration requires evaluation and approval by a licensed provider.
Learn more → Discuss with a provider ↗Sexual-health context
Vitrex lists PT-141 within its sexual-health reference material. It is a subject for confidential provider discussion, not a promised outcome.
Learn more → Discuss with a provider ↗Pigmentation-research context
Vitrex references Melanotan II as source-listed research context. It is educational only and subject to provider evaluation and approval.
Learn more → Discuss with a provider ↗Skin & tissue-support context
Vitrex lists GHK within its skin and tissue-support reference pathway. It is educational context and not a medical recommendation.
Learn more → Discuss with a provider ↗Cellular-energy context
Vitrex references NAD+ in its cellular-energy research material. Any use is subject to evaluation and approval by a licensed provider.
Learn more → Discuss with a provider ↗Reproductive-endocrinology context
Vitrex lists kisspeptin in its reproductive-hormone research context. Human physiology studies exist; it is not an approved medicine.
Learn more → Discuss with a provider ↗GLP-1 · FDA-approved medicine
An approved prescription medicine for type 2 diabetes and chronic weight management — listed so approved options are visible next to research peptides.
Learn more → Discuss with a provider ↗GIP/GLP-1 · FDA-approved medicine
An approved dual-agonist prescription medicine (Mounjaro, Zepbound). Whether it is appropriate is a prescribing decision after intake.
Learn more → Discuss with a provider ↗Daily GLP-1 · FDA-approved
First-generation GLP-1 medicine with generics available. Listed for cost and availability context.
Learn more → Discuss with a provider ↗Triple agonist · phase 3 trials
Investigational; not approved anywhere. Listed because it is widely discussed and sold as unapproved copies.
Learn more → Discuss with a provider ↗Amylin analogue · phase 3 trials
Investigational, studied alone and with semaglutide (CagriSema). Not available outside trials.
Learn more → Discuss with a provider ↗Approved for labour · behavioural research
Injectable oxytocin is approved for obstetric use; intranasal behavioural uses are research-stage.
Learn more → Discuss with a provider ↗Approved medicines · misread research
Vasopressin and desmopressin are approved for specific indications; the online 'social peptide' framing is thin.
Learn more → Discuss with a provider ↗BPC-157 substitute context
A related sequence marketed after compounding restrictions on BPC-157, with less published data than the original.
Learn more → Discuss with a provider ↗Tripeptide antioxidant
Oral supplement, IV drip and injection contexts explained; injectable use is not FDA-approved.
Learn more → Discuss with a provider ↗Not a peptide · mouse data
A small-molecule NNMT inhibitor sold alongside peptides. No human trials.
Learn more → Discuss with a provider ↗Not a peptide · mouse data
An experimental ERR agonist behind 'exercise pill' headlines. No human data.
Learn more → Discuss with a provider ↗Products require evaluation and approval by a licensed provider. Individual results are not implied or guaranteed.
Free intake · 10 min · physician-reviewed
Start medical intakeBefore you go
One short guide to what the research does and does not show, plus new explainers as we publish them. No sales emails, no medical advice, unsubscribe any time.
Or start the free intake instead →